April 22 (Reuters) - AstraZeneca (AZN.L), opens new tab has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America ...

BNP Paribas Exane initiated coverage of AstraZeneca (AZN) with an Outperform rating and $75 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

AstraZeneca AB and AstraZeneca UK Limited are embroiled in a critical legal battle against Glenmark Pharmaceuticals Europe Limited, as they appeal a decision made by Deputy High Court Judge Michael ...

Many learned through the TV news stations or in the Houston Chronicle, which led with the story on its front page. The Post had a head start. It was founded in 1880, as Houston was growing from a ...

Three Houston Chronicle reporters have been recognized as finalists for the Livingston Award, a national journalism award that recognizes overall excellence in reporting and storytelling among ...

AstraZeneca has rejoined PhRMA as it expands its “presence in the United States with significant investments in research, development and manufacturing,” Pascal Soriot, AZ’s CEO, said in a ...

BTIG notes that shares of Tempus AI (TEM) are up on news that the company signed a $200M expanded strategic agreement with AstraZeneca (AZN) and Pathos AI, where the three companies will ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

When AstraZeneca gobbled up Alexion Pharmaceuticals in one of the biggest-ever takeovers of a Boston company, there was some hope it might mean more jobs here instead of the cuts that often follow ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...